JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study

  • 0Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Journal of Thoracic Disease +

|

June 18, 2025

|

June 18, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Pre-neoadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) predict outcomes in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. These markers are crucial for assessing recurrence-free and overall survival post-surgery.

Area Of Science

  • Oncology
  • Thoracic Surgery
  • Cancer Biomarkers

Background

  • Neoadjuvant therapy enhances surgical outcomes and survival in non-small cell lung cancer (NSCLC).
  • Limited research exists on prognostic factors influencing postoperative survival and recurrence after neoadjuvant treatment for NSCLC.
  • This study identifies key prognostic factors for lung resection patients undergoing neoadjuvant therapy.

Purpose Of The Study

  • To identify significant prognostic factors for recurrence-free survival (RFS) and overall survival (OS) after lung resection in NSCLC patients who received neoadjuvant therapy.
  • To evaluate the predictive value of pre-neoadjuvant biomarkers and imaging findings for postoperative outcomes.

Main Methods

  • Analysis of 102 NSCLC cases treated with neoadjuvant therapy.
  • Kaplan-Meier and multivariable Cox regression models to assess RFS and OS.
  • Statistical comparisons using t-tests and Chi-square tests.

Main Results

  • Pre-neoadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) significantly predicted both RFS and OS in NSCLC patients.
  • CEA and NLR showed stronger predictive power for RFS than OS.
  • Tumor size reduction (>50%) on post-neoadjuvant CT correlated with minimal pathological response.
  • Age, pre-neoadjuvant CEA, NLR, PD-1 levels, and mediastinal lymph node changes were associated with tumor recurrence.

Conclusions

  • Pre-neoadjuvant CEA and NLR are significant predictors of postoperative survival in NSCLC patients.
  • Tumor size reduction and programmed cell death protein 1 (PD-1) levels are important considerations for clinical decision-making post-neoadjuvant therapy.

Keywords: